BR112023020574A2 - Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos - Google Patents

Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos

Info

Publication number
BR112023020574A2
BR112023020574A2 BR112023020574A BR112023020574A BR112023020574A2 BR 112023020574 A2 BR112023020574 A2 BR 112023020574A2 BR 112023020574 A BR112023020574 A BR 112023020574A BR 112023020574 A BR112023020574 A BR 112023020574A BR 112023020574 A2 BR112023020574 A2 BR 112023020574A2
Authority
BR
Brazil
Prior art keywords
nkp46
methods
antibodies targeting
antibody molecules
bispecific antibody
Prior art date
Application number
BR112023020574A
Other languages
English (en)
Inventor
Daniel Teper
Jean Kadouche
Wei Li
Original Assignee
Cytovia Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovia Therapeutics Llc filed Critical Cytovia Therapeutics Llc
Publication of BR112023020574A2 publication Critical patent/BR112023020574A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

anticorpos biespecíficos alvejando nkp46 e cd38 e métodos de uso dos mesmos. esta invenção fornece moléculas de anticorpos biespecíficos que se ligam especificamente a nkp46 e cd38. a divulgação refere-se ainda a terapias de combinação compreendendo as moléculas de anticorpo biespecífico. as moléculas de anticorpo biespecífico podem ser usadas para tratar, prevenir e/ou diagnosticar câncer ou condições ou distúrbios infecciosos associados a células que expressam nkp46 e/ou cd38.
BR112023020574A 2021-04-05 2022-04-05 Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos BR112023020574A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170917P 2021-04-05 2021-04-05
PCT/US2022/023501 WO2022216723A1 (en) 2021-04-05 2022-04-05 Bispecific antibodies targeting nkp46 and cd38 and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112023020574A2 true BR112023020574A2 (pt) 2023-12-12

Family

ID=83545702

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023020574A BR112023020574A2 (pt) 2021-04-05 2022-04-05 Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos

Country Status (10)

Country Link
US (1) US20240199756A1 (pt)
EP (1) EP4320164A1 (pt)
JP (1) JP2024513262A (pt)
KR (1) KR20240021153A (pt)
CN (1) CN117545781A (pt)
BR (1) BR112023020574A2 (pt)
CA (1) CA3216053A1 (pt)
IL (1) IL307468A (pt)
MX (1) MX2023011776A (pt)
WO (1) WO2022216723A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016022385A2 (pt) * 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
AU2016284871B2 (en) * 2015-06-23 2022-09-29 Innate Pharma Multispecific NK engager proteins
WO2019011855A1 (en) * 2017-07-10 2019-01-17 Innate Pharma ANTIBODIES NEUTRALIZING SIGLEC-9

Also Published As

Publication number Publication date
WO2022216723A1 (en) 2022-10-13
WO2022216723A9 (en) 2023-08-31
CN117545781A (zh) 2024-02-09
KR20240021153A (ko) 2024-02-16
JP2024513262A (ja) 2024-03-22
CA3216053A1 (en) 2022-10-13
IL307468A (en) 2023-12-01
MX2023011776A (es) 2023-11-29
US20240199756A1 (en) 2024-06-20
EP4320164A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
UY38236A (es) COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
BR112022017930A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112019002168A2 (pt) anticorpos trivalentes bispecíficos ligantes a claudina6 ou claudina18.2 e cd3 para o tratamento de doenças cancerígenas que expressam claudina
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
EA201691858A1 (ru) Композиции антител для лечения опухолей
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
PE20181368A1 (es) Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas
BR112021025259A2 (pt) Composições e métodos para tratar câncer
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
BR112012023010A8 (pt) Anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
BR112018067951A2 (pt) moléculas que se ligam a ilt7 e métodos de uso destas
BR112018072066A2 (pt) moléculas de ligação específicas para fcgamariia e uso das mesmas
BR112015029300A2 (pt) Anticorpo biespecífico, composição farmacêutica compreendendo o mesmo, seus usos, usos de um anticorpo anti-ccl2, e um anticorpo anti-loxl2, ou seus fragmentos e kit
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
BR112022012093A2 (pt) Anticorpos contra integrina alfa 11 beta 1
BR112019008279A2 (pt) uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
BR112023020574A2 (pt) Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos
MX2020009902A (es) Anticuerpos con especificidad dual para pd-l1 y pd-l2 humanos y metodos de uso de los mismos.
BR112023020572A2 (pt) Anticorpos biespecíficos direcionados a nkp46 e gpc3 e métodos de uso dos mesmos
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: CYTOVIA THERAPEUTICS, LLC. (US)